Could New Medigus CEO Add Cannabis to the Lineup?

New Medigus (MDGS, MDGSW) CEO Liron Carmel also happens to be the CEO of cannabis powder producer CannaPowder (CAPD). Mr. Carmel will retain his role as CEO of CannaPowder and lead both companies

Can you say endoscopy with a side of cannabis to ease the procedure?

Medigus makes the MUSE system. An endoscopic device used to treat
GERD (gastroesophageal reflux disease).

Medigus warrants trade under the symbol MDGSW and are exercisable at $3.50 per one ADS, or one share of MDGS. The warrants expire July 23, 2023.

Two points. First, the appointment of CEO Carmel could cause volatility in the stock. Any time a new CEO takes the helm volatility can ensue.

Two, any announcement that Medigus is going to somehow become involved in the red hot cannabis industry could send the shares higher. It may be a stretch, but warrant holders don’t need a lot to see a move in the warrants.

This is a possible volatility play for those interested in taking a position in MDGSW. With a +4 year timeframe on the warrants, and an exercise price in sight of the current common price, the valuation of the warrants at around $.50 appears reasonable.